In this same indication, Eliquis has an FDA PDUFA date of 8/24/14 (#msg-95178866).
Competitor, Xarelto has been approved for VTE treatment and secondary prevention in the US (#msg-81103054) and EU (#msg-80711606) since late 2012 and thus has a pretty big head start in this new indication for Eliquis.
Both drugs are approved in multiple jurisdictions for AF/stroke prevention and for primary VTE prevention following orthopedic surgery. Xarelto is also approved for ACS in the EU (#msg-88290069) but not the US (#msg-97335112).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.